Volume : 10, Issue : 05, May – 2023
Title:
68.A REVIEW ON ADVERSE DRUG REACTIONS IN DRUG RESISTANCES TUBERCULOSIS AND ITS MANAGEMENT
Authors :
Vishnu priya. B. P*, Dr Prasobh G.R, Mr. E. Sam Jeeva Kumar, Ms. Anjana U.J, Ms. Binisha S.K, Ms. Arathy Sreenivasan, Ms. Simchu R.B
Abstract :
Tuberculosis is a contagious disease caused by mycobacterium tuberculosis, leading to increased mortality and morbidity. Although many new diagnostic tests and treatments have emerged for TB, there is still a big question as to why it is not ending. The disease roots easily due to many confounding factors such as patient noncompliance, development of ADR during treatment and the evolution of drug resistance. The drugs used in treatment have a higher proportion of side effects. The majority patients required treatment modification due to ADRs. The proper identification, reporting, management, or prevention can increase compliance and positive outcomes of therapy.
Keywords: Tuberculosis, Tuberculosis Treatment, Tuberculosis drugs, ADR management, Drug-resistant Tuberculosis.
Cite This Article:
Please cite this article in press Vishnu Priya. B. P et al, A Review On Adverse Drug Reactions In Drug Resistances Tuberculosis And Its Management., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
References:
1. DR. Mandan Kaushik. Textbook of pathophysiology: page no: 382.
2. Lienhardt C et al. Efficacy and Safety of a four-drug fixed dose combination regimen compared with separate drugs for treatment of pulmonary TB. The Study C randomized controlled trial. JAMA. 2011; 305:1415. 3.
3. Lin HH et al. Association between tobacco smoking and active TB in Taiwan: prospective cohort study Am J Respir Crit Care Med. 2009; 180:475.
4. Mazurek GH et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection United States, 2010.
5. World Health Organization. Global tuberculosis report 2021
6. Peloquin CA Bering SE. infection caused by Mycobacterium tuberculosis. Ann pharma other 1994; 28:72.
7. Daniel TM et al Tuberculosis. In Wilson the et al eds. Harrison’s principles of internal medicine. 12th edition New York MC Graw Thill 1991:637.8.
8. Barbara G. Wells, Joseph T. Dipiro, Terry L. Schwinghammer, Cecily v. Dipiro. Pharmacotherapy handbook: seventh edition page no: 532-533.
9. Applied therapeutics the clinical use of drugs 7th edition Marry Anne Kode Kimble or Lloyd Yee young page no 59.16
10. Roger walker and Cate whittlesea. Clinical pharmacy and therapeutics: 5th edition. Page no: 608-618.
11. David P. Maison journal of clinical Tuberculosis and other Mycobacterium Diseases.
12. 10. Hobby, G.L.; Lenert, T.F. The in vitro action of antituberculosis agents against multiplying and non-multiplying microbial cells. Am. Rev. Tuberc, 1957, 76, 1031-1048.
13. Dover, L.G.; Geoffrey, D. Current Status and Research Strategies in Tuberculosis Drug Development. J. Med. Chem., 2011, 54, 6157-6165
14. Kolyva, A.S.; Karakousis, P.C. Old and New TB Drugs: Mechanisms of Action and Resistance. Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance. In. Tech., 2012, 12, 209-232.
15. Kaona, F.A.; Tuba, M.; Siziya, S.; Sikaona, L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health, 2004, 4, 68.
16. The Global Tuberculosis Program. www.who.int/tb/about/en (Accessed on May 23, 2015).
17. Shah, N.S.; Wright, A.; Bai, A.H.; Barrera, L. Worldwide Emergence of Extensively Drug-resistant Tuberculosis. Emerg. Infect. Dis., 2006, 13, 380-387.
18. Revised National Tuberculosis Control Programme DOTS-Plus Guidelines, Central TB Division-Directorate General of Health Services, Ministry of Health & Family Welfare Nirman Bhavan: New Delhi, 2010.
19. Veziris, N.; Pernot, T.C.; Aubry, A.; Jarlier. V. Fluoroquinolone containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrobial Agents Chemother., 2003,10, 3117-3122.
20. Vivekanandan Kalaiselvan, Shatrunajay Shukala, Santhanakrishnan Ramesh kumar, Nikita Mishra, Pawan kumar and Rajeev Singh Raghuvanshi. Adverse drug reactions associated with anti- tuberculosis therapy.
21. National action plan for combating multidrug-resistant tuberculosis.